GlassScriptPhysician profile
Paul A Hurst
NPI 1992717615
$4,807.20
in general payments reported to CMS, 2019-2025
35 companies · $692 in 2025
The $692 reported for 2025 was more than what 77% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,053 · 2022: $1,480 · 2023: $1,271 · 2024: $312 · 2025: $692.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,206 · Education: $68.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,206.32 |
| Education | $68.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $535.43 | 2021-2023 | Xiaflex, Aveed, Edex |
| Astellas Pharma US INC | $416.84 | 2021-2024 | Xtandi, Myrbetriq |
| Abbvie INC. | $375.15 | 2021-2025 | |
| Janssen Biotech, INC. | $301.62 | 2021-2025 | Erleada |
| Sumitomo Pharma America, INC. | $288.56 | 2023-2025 | Orgovyx, Gemtesa |
| Dendreon Pharmaceuticals LLC | $255.95 | 2021-2024 | Provenge |
| Olympus America INC. | $254.52 | 2022-2025 | Itind System, Soltive |
| Urogen Pharma, INC. | $206.92 | 2021-2024 | Jelmyto |
| Pfizer INC. | $206.68 | 2021-2025 | |
| Antares Pharma, INC. | $185.96 | 2021-2023 | Xyosted, Tlando, Nocdurna |
| Rochester Medical Corporation | $159.58 | 2021-2022 | |
| Amgen INC. | $151.02 | 2021-2023 | Prolia |
| Progenics Pharmaceuticals, INC. | $150.26 | 2022-2025 | Pylarify |
| Allergan, INC. | $129.54 | 2021 | |
| Urovant Sciences INC | $117.09 | 2021-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $115.33 | 2021-2024 | Axonics |
| Procept Biorobotics Corporation | $108.91 | 2022 | |
| Blue Earth Diagnostics | $97.53 | 2021-2023 | |
| Boston Scientific Corporation | $89.64 | 2025 | Axonics - Pne Lead Implant Kit 1 (Eu), Axonics, Ams 800 Artificial Urinary Sphincter |
| Angiodynamics, INC. | $77.11 | 2021-2022 | |
| Edap Technomed INC | $75.81 | 2024-2025 | |
| Teleflex LLC | $73.56 | 2022-2023 | Urolift |
| Merck Sharp & Dohme LLC | $58.86 | 2021-2025 | Lynparza |
| Bayer Healthcare Pharmaceuticals INC. | $54.86 | 2021-2023 | |
| Endo USA, INC. | $45.26 | 2025 | Xiaflex |
| Astrazeneca Pharmaceuticals LP | $45.26 | 2021-2022 | |
| Coloplast Corp | $41.19 | 2021-2022 | |
| Tolmar, INC. | $39.81 | 2025 | Eligard, Jatenzo |
| Smith+Nephew, INC. | $37.15 | 2022-2024 | Stravix |
| Myovant Sciences INC. | $28.14 | 2021 | |
| Novartis Pharmaceuticals Corporation | $21.78 | 2023 | |
| Civco Medical Instruments | $20.82 | 2025 | |
| Ferring Pharmaceuticals INC. | $15.01 | 2025 | Adstiladrin |
| Convatec INC. | $14.77 | 2023 | |
| Travere Therapeutics, INC. | $11.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Hurst listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.